Table 1 Univariate analysis of 7 days mortality in patients with extended-spectrum beta-lactamase (ESBL)-positive or -negative E. coli and K. pneumoniae bloodstream infection (during hospitalization)
Parameter | Survived until 7 days after BSI | Died within 7 days after BSI | 7-days Mortality | P-value | Survived/ discharged after BSI | Died in-hospital after BSI | In-hospital Mortality | P-value |
|---|---|---|---|---|---|---|---|---|
Number (%) | Number (%) | Number (%) | Number (%) | |||||
Patients | 1.690 (100 %) | 161 (100 %) | 8.7 % | 1485 (100 %) | 366 (100 %) | 19.8 % | ||
K. pneumoniae | 319 (18.9 %) | 33 (20.5 %) | 9.4 % | 0.616 | 264 (17.8 %) | 88 (24.0 %) | 25.0 % | 0.006 |
E. coli | 1371 (81.1 %) | 128 (79.5 %) | 8.5 % | 1221 (82.2 %) | 278 (76.0 %) | 18.5 % | ||
ESBL-positive | 219 (13.0 %) | 25 (15.5 %) | 10.2 % | 0.357 | 183 (12.3 %) | 61 (16.7 %) | 25.0 % | 0.028 |
Hospital mortality | 205 (12.1 %) | 161 (100.0 %) | 44.0 % | <0.001 | - | 366 (100.0 %) | 100.0 % | n.a. |
Polymicrobial | 198 (11.7 %) | 27 (16.8 %) | 12.0 % | 0.061* | 160 (10.8 %) | 65 (17.8 %) | 28.9 % | <0.001* |
Age (years)a | 65 (52–73)a | 67 (57–76)a | n.a. | 0.019* | 65 (52–73)a | 66 (54–74)a | n.a. | 0.134* |
Male | 929 (55.0 %) | 93 (57.8 %) | 9.1 % | 0.496 | 799 (53.8 %) | 223 (60.9 %) | 21.8 % | 0.014 |
Hospital onset | 746 (44.1 %) | 84 (52.2 %) | 10.1 % | 0.050* | 612 (41.2 %) | 218 (59.6 %) | 26.3 % | <0.001* |
ICU stay | 1.072 (63.4 %) | 125 (77.6 %) | 10.4 % | <0.001* | 896 (60.3 %) | 301 (82.2 %) | 25.1 % | <0.001* |
Charlson comorbidity indexa | 5 (3–8)a | 8 (6–10)a | n.a. | <0.001 | 5 (3–8)a | 8 (6–10)a | n.a. | <0.001 |
Heart disease | 275 (16.3 %) | 47 (29.2 %) | 14.6 % | <0.001* | 215 (14.5 %) | 107 (29.2 %) | 33.2 % | <0.001* |
Cerebrovascular disease | 243 (14.4 %) | 31 (19.3 %) | 11.3 % | 0.096* | 202 (13.6 %) | 72 (19.7 %) | 26.3 % | 0.003* |
Neurologic disease | 123 (7.3 %) | 11 (6.8 %) | 8.2 % | 0.835 | 112 (7.5 %) | 22 (6.0 %) | 16.4 % | 0.311 |
Lung disease | 218 (12.9 %) | 24 (14.9 %) | 9.9 % | 0.470 | 181 (12.2 %) | 61 (16.7 %) | 25.2 % | 0.023 |
Gastrointestinal disease | 53 (3.1 %) | 12 (7.5 %) | 18.5 % | 0.004* | 36 (2.4 %) | 29 (7.9 %) | 44.6 % | <0.001* |
Rheumatic disease | 50 (3.0 %) | 2 (1.2 %) | 3.8 % | 0.208 | 44 (3.0 %) | 8 (2.2 %) | 15.4 % | 0.420 |
Liver disease | 258 (15.3 %) | 53 (32.9 %) | 17.0 % | <0.001* | 180 (12.1 %) | 131 (35.8 %) | 42.1 % | <0.001* |
Diabetes | 422 (25.0 %) | 48 (29.8 %) | 10.2 % | 0.177 | 366 (24.6 %) | 104 (28.4 %) | 22.1 % | 0.138 |
Renal disease | 711 (42.1 %) | 115 (71.4 %) | 13.9 % | <0.001* | 565 (38.0 %) | 261 (71.3 %) | 31.6 % | <0.001* |
Cancer/immunological disease | 672 (39.8 %) | 75 (46.6 %) | 10.0 % | 0.092* | 571 (38.5 %) | 176 (48.1 %) | 23.6 % | 0.001* |